SynAct carries out a directed share issue and raises proceeds of SEK 80 million - English version - Swedish version published 08:00 today
SynAct Pharma AB (publ) (”SynAct” or ”the Company”) has, in accordance with the announcement made in a press release yesterday, successfully completed a directed share issue of 1,600,000 shares at a price of SEK 50 per share (the “Directed Share Issue”). Due to the Directed Share Issue being multiple times over-subscribed by a large number of professional investors, the gross proceeds in the Directed Share Issue were increased from the SEK 55 million indicated in the Company’s press release yesterday. Through the Directed Share Issue, the Company will receive gross proceeds of SEK 80 million.